Radius Healths says elacestrant still 'shows promise' in advanced breast cancer
Radius Health provided an update on data from the Phase 1 005 clinical study of elacestrant, an oral selective estrogen receptor degrader, in patients with estrogen receptor positive breast cancer. The data were presented at a Spotlight Presentation during the 2017 San Antonio Breast Cancer Symposium. Elacestrant recently received Fast Track designation from the U.S. Food and Drug Administration. There are 40 patients that have been treated at the 400 mg dose in the elacestrant Phase I dose escalation and expansion cohorts. All study participants are heavily pretreated ER+, HER2-negative, advanced breast cancer patients that have received a median of three prior lines of systemic therapy and have evaluable advanced or metastatic disease. Of the enrolled patients, 22 patients met the RECIST measurable disease criteria at baseline and there were 6 confirmed partial responses in this group. Elacestrant was well-tolerated with the most common adverse events being low grade nausea, dyspepsia and vomiting. "It is quite encouraging to see the clinical activity with elacestrant in the heavily pretreated advanced patient population, and further therapeutic development is warranted for patients with hormone receptor positive breast cancer", commented Dr. Aditya Bardia, Director of Precision Medicine and attending physician at Center for Breast Cancer, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.